The Effects of Low Molecular Weight Heparin on Microalbuminuria in Patients with Type II Diabetes Mellitus

• Published in: Boğaziçi tıp dergisi Vol. 7; no. 2; pp. 58 - 62
• Main Authors: Meltem Sertbaş, Mutlu Niyaz, Güven Çetin, Nalan Okuroğlu, Yaşar Sertbaş
• Format: Journal Article
• Language: English
• Published: Kare Publishing 01.06.2020
• Subjects: low molecular weight heparin; microalbuminuria; nadroparin
• ISSN: 2149-0287
• DOI: 10.14744/bmj.2020.02419

INTRODUCTION[|]Diabetic nephropathy is one of the major complications of diabetes, with a frequency of 20-40% and high mortality. Different treatment modalities are required for the progression and prevention of nephropathy apart from the conventional treatment approaches. The present study aims to investigate the effects of low molecular weight heparin, Nadroparin on microalbuminuria.[¤]METHODS[|]Forty-four Type II diabetic patients between the ages of 30-70 who were followed up from the internal medicine outpatient clinic and service were included in this study. Nadroparin, an LMWH for one month, was administered subcutaneously at a dose of 3075 IU to randomly selected 22 patients. The other 22 patients were followed up without any treatment as a control group.[¤]RESULTS[|]There was a significant decrease in urea (43.2+-18.3 and 34.9+-7.9) and creatinine (1.13+-0.32 and 0.9+-0.3) values between basal and after 1-month treatment of Nadroparin (p<0.05). Meanwhile, there was not any significant difference between the basal values and values after in the control group (p>0.05). There was a slight increase in creatinine clearance values after one month of treatment, which was not statistically significant (p>0.05). Although a 15% decrease in patients was achieved after treatment with Nadroparin, the change in microalbuminuria (137.6+-99.3 and 116.4+-114.1) was not significant.[¤]DISCUSSION AND CONCLUSION[|]As a result, in our study, although it was not statistically significant, there were a decrease of microalbuminuria levels after the application of Nadroparin with LMWH, and our findings suggest that it should be considered in patients with microalbuminuria, even if it is not a part of standard treatment.[¤]